Mulvihill, Erin E <br/><br/>
Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.  [electronic resource] 

 -  Arteriosclerosis, thrombosis, and vascular biology  Apr 2010 
 - 742-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4636 
<br/><br/><label>Standard No.: </label>10.1161/ATVBAHA.109.201095  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Aorta--drug effects<br/>Aortic Diseases--etiology<br/>Atherosclerosis--etiology<br/>Cholesterol--metabolism<br/>Diet, Atherogenic<br/>Dietary Fats<br/>Disease Models, Animal<br/>Disease Progression<br/>Fatty Liver--etiology<br/>Flavanones--pharmacology<br/>Hyperinsulinism--etiology<br/>Hyperlipidemias--drug therapy<br/>Hypolipidemic Agents--pharmacology<br/>Male<br/>Mice<br/>Mice, Inbred C57BL<br/>Mice, Knockout<br/>Obesity--etiology<br/>Receptors, LDL--deficiency<br/>Time Factors<br/>Triglycerides--metabolism